These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

915 related items for PubMed ID: 30707758

  • 1. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
    D'Adda M, Farina M, Schieppati F, Borlenghi E, Bottelli C, Cerqui E, Ferrari S, Gramegna D, Pagani C, Passi A, Maifredi A, Tucci A, Capucci MA, Ruggeri G, Rossi G.
    Cancer; 2019 May 15; 125(10):1674-1682. PubMed ID: 30707758
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript.
    Lucas CM, Harris RJ, Giannoudis A, Davies A, Knight K, Watmough SJ, Wang L, Clark RE.
    Haematologica; 2009 Oct 15; 94(10):1362-7. PubMed ID: 19713230
    [Abstract] [Full Text] [Related]

  • 6. The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia.
    Ercaliskan A, Eskazan AE.
    Cancer; 2018 Oct 01; 124(19):3806-3818. PubMed ID: 29694669
    [Abstract] [Full Text] [Related]

  • 7. Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib. A First of Its Kind Study on CML Patients of Kashmir.
    Azad NA, Shah ZA, Pandith AA, Khan MS, Rasool R, Rasool J, Aziz SA.
    Asian Pac J Cancer Prev; 2018 Jun 25; 19(6):1479-1485. PubMed ID: 29936718
    [Abstract] [Full Text] [Related]

  • 8. No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib.
    Pfirrmann M, Evtimova D, Saussele S, Castagnetti F, Cervantes F, Janssen J, Hoffmann VS, Gugliotta G, Hehlmann R, Hochhaus A, Hasford J, Baccarani M.
    J Cancer Res Clin Oncol; 2017 May 25; 143(5):843-850. PubMed ID: 28083711
    [Abstract] [Full Text] [Related]

  • 9. Impact of the BCR-ABL1 fusion transcripts on different responses to Imatinib and disease recurrence in Iranian patients with Chronic Myeloid Leukemia.
    Rostami G, Hamid M, Jalaeikhoo H.
    Gene; 2017 Sep 05; 627():202-206. PubMed ID: 28627443
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib.
    Marcé S, Xicoy B, García O, Cabezón M, Estrada N, Vélez P, Boqué C, Sagüés M, Angona A, Teruel-Montoya R, Ferrer-Marín F, Amat P, Hernández-Boluda JC, Ibarra MM, Anguita E, Cortés M, Fernández-Ruiz A, Fontanals S, Zamora L, On Behalf Of The Grupo Español de Leucemia Mieloide Crónica Gelmc.
    J Clin Med; 2021 Jul 16; 10(14):. PubMed ID: 34300312
    [Abstract] [Full Text] [Related]

  • 12. Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution.
    Cerveira N, Loureiro B, Bizarro S, Correia C, Torres L, Lisboa S, Vieira J, Santos R, Pereira D, Moreira C, Chacim S, Domingues N, Espírito-Santo A, Oliveira I, Moreira I, Viterbo L, Martins Â, Teixeira MR, Mariz JM.
    BMC Cancer; 2018 Dec 12; 18(1):1245. PubMed ID: 30541488
    [Abstract] [Full Text] [Related]

  • 13. Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice.
    Breccia M, Efficace F, Colafigli G, Scalzulli E, Di Prima A, Martelli M, Foà R.
    Expert Rev Hematol; 2020 Dec 12; 13(12):1311-1318. PubMed ID: 33205694
    [Abstract] [Full Text] [Related]

  • 14. Comparison of molecular responses and outcomes between BCR::ABL1 e14a2 and e13a2 transcripts in chronic myeloid leukemia.
    Su YJ, Kuo MC, Chen TY, Wang MC, Yang Y, Ma MC, Lin TL, Lin TH, Chang H, Teng CJ, Hsiao PC, Chen CC, Wang PN, Shih LY.
    Cancer Sci; 2022 Oct 12; 113(10):3518-3527. PubMed ID: 35869805
    [Abstract] [Full Text] [Related]

  • 15. Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
    Cayssials E, Torregrosa-Diaz J, Gallego-Hernanz P, Tartarin F, Systchenko T, Maillard N, Desmier D, Machet A, Fleck E, Corby A, Motard C, Denis G, Herbelin A, Gombert JM, Roy L, Ragot S, Leleu X, Guilhot F, Chomel JC.
    Cancer; 2020 Aug 01; 126(15):3438-3447. PubMed ID: 32459375
    [Abstract] [Full Text] [Related]

  • 16. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
    Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, Janssen JJWM, Mayer J, Koskenvesa P, Panayiotidis P, Olsson-Strömberg U, Martinez-Lopez J, Rousselot P, Vestergaard H, Ehrencrona H, Kairisto V, Machová Poláková K, Müller MC, Mustjoki S, Berger MG, Fabarius A, Hofmann WK, Hochhaus A, Pfirrmann M, Mahon FX, EURO-SKI investigators.
    Lancet Oncol; 2018 Jun 01; 19(6):747-757. PubMed ID: 29735299
    [Abstract] [Full Text] [Related]

  • 17. Monitoring Treatment-Free Remission by Droplet Digital PCR in CML Patients with Deep Molecular Response to Tyrosine Kinase Inhibitor: An Analysis Based on Real-World Data.
    Zhu G, Yang Y, Wang H, Xie J, Hu J, Guo W, Zhang L, Liu Z, Chen X, Chang J, Xu J, Tan Y.
    Ann Clin Lab Sci; 2020 Sep 01; 50(5):591-599. PubMed ID: 33067205
    [Abstract] [Full Text] [Related]

  • 18. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.
    Clark RE, Polydoros F, Apperley JF, Milojkovic D, Rothwell K, Pocock C, Byrne J, de Lavallade H, Osborne W, Robinson L, O'Brien SG, Read L, Foroni L, Copland M.
    Lancet Haematol; 2019 Jul 01; 6(7):e375-e383. PubMed ID: 31201085
    [Abstract] [Full Text] [Related]

  • 19. Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.
    Verma D, Kantarjian HM, Jones D, Luthra R, Borthakur G, Verstovsek S, Rios MB, Cortes J.
    Blood; 2009 Sep 10; 114(11):2232-5. PubMed ID: 19531657
    [Abstract] [Full Text] [Related]

  • 20. Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia.
    Shanmuganathan N, Pagani IS, Ross DM, Park S, Yong ASM, Braley JA, Altamura HK, Hiwase DK, Yeung DT, Kim DW, Branford S, Hughes TP.
    Blood; 2021 Mar 04; 137(9):1196-1207. PubMed ID: 32871588
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.